Loading...
Market
How many companies will adopt Exscientia's GenAI platform by the end of 2024?
2
Resolution / Starting Odds
0-1 companies • 25%
2-3 companies • 25%
4-5 companies • 25%
More than 5 companies • 25%
Official announcements from Exscientia or the adopting companies
Story
Exscientia Launches AWS-Powered GenAI Platform for Drug Discovery
Jul 10, 2024, 11:13 AM
Exscientia has launched a state-of-the-art GenAI platform to advance drug discovery, built using AWS technology. The platform integrates generative AI drug design and robotic lab automation to accelerate the delivery of high-quality drugs at faster speeds and lower costs. This development signifies a significant shift in the drug discovery landscape, leveraging massive proprietary datasets and AI to produce intelligence that leads to drug production. Jensen Huang highlighted the scale of data and compute reaching an inflection point in this field.
View original story
Similar markets
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%
Insilico Medicine • 25%
Amgen • 25%
Nested Therapeutics • 25%
Other • 25%
Google DeepMind • 25%
Microsoft • 25%
IBM • 25%
Other • 25%
None • 25%
1-2 institutions • 25%
3-5 institutions • 25%
More than 5 institutions • 25%
Insilico Medicine • 25%
Amgen • 25%
Terray Therapeutics • 25%
Other • 25%
Less than 50 • 25%
50-100 • 25%
101-200 • 25%
More than 200 • 25%
Yes • 50%
No • 50%
Amgen • 25%
Genentech • 25%
Regeneron • 25%
Other • 25%
More than 3 new drugs • 25%
2-3 new drugs • 25%
1 new drug • 25%
No new drugs • 25%
0-1 projects • 25%
2-3 projects • 25%
4-5 projects • 25%
More than 5 projects • 25%
No new partnerships • 33%
1-2 new partnerships • 33%
More than 2 new partnerships • 33%